APO Research
Talk to an analyst

APO RESEARCH · REPORT

PMP22 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PMP22 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchPMP22 Antibody Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal PMP22 Antibody Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal PMP22 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PMP22 Antibody Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal PMP22 Antibody Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global PMP22 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PMP22 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PMP22 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PMP22 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PMP22 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PMP22 Antibody market include Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, LSBio, FineTest, EXBIO, Biorbyt and BioLegend, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global PMP22 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PMP22 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PMP22 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PMP22 Antibody market.

PMP22 Antibody Segment by Company

Merck

Boster Biological Technology

United States Biological

Santa Cruz Biotechnology

LSBio

FineTest

EXBIO

Biorbyt

BioLegend

PMP22 Antibody Segment by Type

Polyclonal

Monoclonal

PMP22 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Immunofluorescence

Flow Cytometry

Western Blot

Others

PMP22 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global PMP22 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the PMP22 Antibody key companies, revenue, market share, and recent developments.

3. To split the PMP22 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions PMP22 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PMP22 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze PMP22 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMP22 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PMP22 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMP22 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PMP22 Antibody industry.

Chapter 3: Detailed analysis of PMP22 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of PMP22 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of PMP22 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PMP22 Antibody Industry Trends Table 2. PMP22 Antibody Industry Drivers Table 3. PMP22 Antibody Industry Opportunities and Challenges Table 4. PMP22 Antibody Industry Restraints Table 5. Global PMP22 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PMP22 Antibody Revenue Share by Company (2021-2026) Table 7. Global PMP22 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global PMP22 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global PMP22 Antibody Company, Product Type & Application Table 10. Global PMP22 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global PMP22 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global PMP22 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global PMP22 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global PMP22 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global PMP22 Antibody Sales Value Share by Type (2021-2026) Table 20. Global PMP22 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Immunofluorescence Table 24. Significant Companies of Flow Cytometry Table 25. Significant Companies of Western Blot Table 26. Significant Companies of Others Table 27. Global PMP22 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global PMP22 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global PMP22 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global PMP22 Antibody Sales Value Share by Application (2021-2026) Table 31. Global PMP22 Antibody Sales Value Share by Application (2027-2032) Table 32. Global PMP22 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global PMP22 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global PMP22 Antibody Sales Value Share by Region (2021-2026) Table 35. Global PMP22 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global PMP22 Antibody Sales Value Share by Region (2027-2032) Table 37. Global PMP22 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global PMP22 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global PMP22 Antibody Sales Value Market Share by Country (2021-2026) Table 40. Global PMP22 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global PMP22 Antibody Sales Value Market Share by Country (2027-2032) Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck PMP22 Antibody Product Portfolio Table 46. Merck Recent Development Table 47. Boster Biological Technology Company Information Table 48. Boster Biological Technology Business Overview Table 49. Boster Biological Technology PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Boster Biological Technology PMP22 Antibody Product Portfolio Table 51. Boster Biological Technology Recent Development Table 52. United States Biological Company Information Table 53. United States Biological Business Overview Table 54. United States Biological PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. United States Biological PMP22 Antibody Product Portfolio Table 56. United States Biological Recent Development Table 57. Santa Cruz Biotechnology Company Information Table 58. Santa Cruz Biotechnology Business Overview Table 59. Santa Cruz Biotechnology PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Santa Cruz Biotechnology PMP22 Antibody Product Portfolio Table 61. Santa Cruz Biotechnology Recent Development Table 62. LSBio Company Information Table 63. LSBio Business Overview Table 64. LSBio PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. LSBio PMP22 Antibody Product Portfolio Table 66. LSBio Recent Development Table 67. FineTest Company Information Table 68. FineTest Business Overview Table 69. FineTest PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. FineTest PMP22 Antibody Product Portfolio Table 71. FineTest Recent Development Table 72. EXBIO Company Information Table 73. EXBIO Business Overview Table 74. EXBIO PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. EXBIO PMP22 Antibody Product Portfolio Table 76. EXBIO Recent Development Table 77. Biorbyt Company Information Table 78. Biorbyt Business Overview Table 79. Biorbyt PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Biorbyt PMP22 Antibody Product Portfolio Table 81. Biorbyt Recent Development Table 82. BioLegend Company Information Table 83. BioLegend Business Overview Table 84. BioLegend PMP22 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. BioLegend PMP22 Antibody Product Portfolio Table 86. BioLegend Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. PMP22 Antibody Product Image Figure 2. Global PMP22 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PMP22 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global PMP22 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global PMP22 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global PMP22 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global PMP22 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Immunofluorescence Image Figure 15. Flow Cytometry Image Figure 16. Western Blot Image Figure 17. Others Image Figure 18. Global PMP22 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global PMP22 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global PMP22 Antibody Sales Value Share by Application (2021-2032) Figure 21. Global PMP22 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global PMP22 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America PMP22 Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. North America PMP22 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe PMP22 Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Europe PMP22 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific PMP22 Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific PMP22 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America PMP22 Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. South America PMP22 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa PMP22 Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa PMP22 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt PMP22 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt PMP22 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt PMP22 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Immunofluorescence
  • Flow Cytometry
  • Western Blot
  • Others
Companies covered
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Santa Cruz Biotechnology
  • LSBio
  • FineTest
  • EXBIO
  • Biorbyt
  • BioLegend

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PMP22 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PMP22 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 PMP22 Antibody Market Dynamics
  1. 2.1 PMP22 Antibody Industry Trends
  2. 2.2 PMP22 Antibody Industry Drivers
  3. 2.3 PMP22 Antibody Industry Opportunities and Challenges
  4. 2.4 PMP22 Antibody Industry Restraints
3 PMP22 Antibody Market by Company
  1. 3.1 Global PMP22 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global PMP22 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global PMP22 Antibody Company Ranking (2024-2026)
  4. 3.4 Global PMP22 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global PMP22 Antibody Company Product Type and Application
  6. 3.6 Global PMP22 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global PMP22 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 PMP22 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 PMP22 Antibody Market by Type
  1. 4.1 PMP22 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global PMP22 Antibody Sales Value by Type
  5. 4.2.1 Global PMP22 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PMP22 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global PMP22 Antibody Sales Value Share by Type (2021-2032)
5 PMP22 Antibody Market by Application
  1. 5.1 PMP22 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Immunofluorescence
  5. 5.1.4 Flow Cytometry
  6. 5.1.5 Western Blot
  7. 5.1.6 Others
  8. 5.2 Global PMP22 Antibody Sales Value by Application
  9. 5.2.1 Global PMP22 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global PMP22 Antibody Sales Value by Application (2021-2032)
  11. 5.2.3 Global PMP22 Antibody Sales Value Share by Application (2021-2032)
6 PMP22 Antibody Regional Value Analysis
  1. 6.1 Global PMP22 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PMP22 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global PMP22 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global PMP22 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PMP22 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America PMP22 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe PMP22 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe PMP22 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific PMP22 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific PMP22 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America PMP22 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America PMP22 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa PMP22 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa PMP22 Antibody Sales Value Share by Country, 2025 VS 2032
7 PMP22 Antibody Country-level Value Analysis
  1. 7.1 Global PMP22 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PMP22 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global PMP22 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global PMP22 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA PMP22 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada PMP22 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico PMP22 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany PMP22 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France PMP22 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. PMP22 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy PMP22 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain PMP22 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia PMP22 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands PMP22 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries PMP22 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China PMP22 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan PMP22 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea PMP22 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India PMP22 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia PMP22 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia PMP22 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil PMP22 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina PMP22 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile PMP22 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia PMP22 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru PMP22 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia PMP22 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel PMP22 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE PMP22 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey PMP22 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran PMP22 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt PMP22 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt PMP22 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt PMP22 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck PMP22 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck PMP22 Antibody Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology PMP22 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology PMP22 Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological PMP22 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological PMP22 Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology PMP22 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology PMP22 Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 LSBio
  26. 8.5.1 LSBio Company Information
  27. 8.5.2 LSBio Business Overview
  28. 8.5.3 LSBio PMP22 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 LSBio PMP22 Antibody Product Portfolio
  30. 8.5.5 LSBio Recent Developments
  31. 8.6 FineTest
  32. 8.6.1 FineTest Company Information
  33. 8.6.2 FineTest Business Overview
  34. 8.6.3 FineTest PMP22 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FineTest PMP22 Antibody Product Portfolio
  36. 8.6.5 FineTest Recent Developments
  37. 8.7 EXBIO
  38. 8.7.1 EXBIO Company Information
  39. 8.7.2 EXBIO Business Overview
  40. 8.7.3 EXBIO PMP22 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 EXBIO PMP22 Antibody Product Portfolio
  42. 8.7.5 EXBIO Recent Developments
  43. 8.8 Biorbyt
  44. 8.8.1 Biorbyt Company Information
  45. 8.8.2 Biorbyt Business Overview
  46. 8.8.3 Biorbyt PMP22 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biorbyt PMP22 Antibody Product Portfolio
  48. 8.8.5 Biorbyt Recent Developments
  49. 8.9 BioLegend
  50. 8.9.1 BioLegend Company Information
  51. 8.9.2 BioLegend Business Overview
  52. 8.9.3 BioLegend PMP22 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioLegend PMP22 Antibody Product Portfolio
  54. 8.9.5 BioLegend Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst